Clinical Trials Browser

INDUSTRY × Observational × darolutamide × Clear all

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT06661122 2026-05-19

HAYATE

Recruiting

100 enrolled

Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT07538843 2026-05-15

DARE

Not yet recruiting

800 enrolled

Genitourinary

Non-metastatic Castration-resistant Prostate Cancer

NCT06334120 2026-05-13

An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

Recruiting

600 enrolled

Genitourinary

Non-metastatic Castration-resistant Prostate Cancer

NCT07406282 2026-04-09

Double-DARE

Recruiting

1,400 enrolled

Genitourinary

Prostatic Neoplasms

NCT07344779 2026-04-03

ROAD

Active not recruiting

1,600 enrolled

Genitourinary

Prostatic Neoplasms

NCT05202301 2025-08-11

A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely

Completed

13,779 enrolled

Genitourinary

Prostatic Neoplasms

NCT06013475 2025-06-12

DEAR-EXT

Completed

1,375 enrolled

Genitourinary

Non-metastatic Castration-resistant Prostate Cancer

NCT06498921 2024-10-24

BELBEQA

Completed

106 enrolled

Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT06204302 2024-04-09

ARENA

Completed

1,800 enrolled

Genitourinary

Non-metastatic Prostate Cancer

NCT05362149 2024-03-20

DEAR

Completed

870 enrolled

Genitourinary

Non-metastatic Castration-resistant Prostate Cancer

Clinical Trials

23146

HAYATE

DARE

An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

Double-DARE

ROAD

A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely

DEAR-EXT

BELBEQA

ARENA

DEAR